Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer |
| |
Authors: | Javier Castro de Carpeño M. González Barón J. Aguiar J. I. Chacón J. Feliu M. J. García C. Madroñal A. Colmenarejo J. J. Sánchez A. Ordóñez |
| |
Affiliation: | (1) Department of Medical Oncology, La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain;(2) Department of Medical Oncology, Hospital Dr. Negrín, Las Palmas, Spain;(3) Department of Medical Oncology, Hospital Virgen de la Salud, Toledo, Spain;(4) Department of Medical Oncology, Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain;(5) Department of Medical Oncology, Clínica Corachan, Barcelona, Spain;(6) Department of Medical Oncology, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain;(7) Department of Preventive Medicine, Autonomous University of Madrid, Madrid, Spain |
| |
Abstract: | Purpose: Improving chemotherapeutic efficacy in non-small cell lung cancer (NSCLC) will require the development of new strategies to better use currently available agents. To assess the efficacy and safety of a biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer. Methods: Patients with selected stage IIIb (pleural effusion)/stage IV NSCLC, performance status of 0–2 and normal organ function were eligible. Treatment consisted of cisplatin 100 mg/m2 on day 1 plus gemcitabine, 1,000 mg/m2 and vinorelbine 25 mg/m2 on days 1 and 15 every 28 days. Results: Of the 40 patients enrolled and assessable for response, there were five (12.5%) with confirmed complete response and 14 (35%) with a confirmed partial response for an overall response rate of 47.5%. Nine patients had stable disease while 12 (30%) progressed. Median progression-free survival and overall survival for all patients were 6.3 and 11.1 months, respectively. Toxicity was principally hematologic, with grade 3–4 neutropenia in 30%, and grade 3–4 nausea/vomiting in 22.5%. There were no treatment-related deaths. Conclusions: The biweekly regimen of cisplatin, gemcitabine and vinorelbine is associated with a high rate of response, lesser toxicity than other three-drug regimens and no benefit of survival. Therefore, the regimen under study may be an appealing alternative when considering other treatment modalities for advanced lung cancer, such as neoadjuvant therapy. |
| |
Keywords: | Non-small-cell lung carcinoma Gemcitabine Cisplatin Chemotherapy Vinorelbine Triplets |
本文献已被 PubMed SpringerLink 等数据库收录! |
|